Scarica l'app Stockscreener
27.93
2.51%
-0.7262
Precedente Chiudi:
$28.66
Aprire:
$28.57
Volume 24 ore:
248.60K
Relative Volume:
0.17
Capitalizzazione di mercato:
$1.63B
Reddito:
$32.87M
Utile/perdita netta:
$674.31M
Rapporto P/E:
2.459
EPS:
11.36
Flusso di cassa netto:
$-330.11M
1 W Prestazione:
+2.76%
1M Prestazione:
+13.63%
6M Prestazione:
-31.11%
1 anno Prestazione:
-21.03%
Intervallo 1D:
$27.83
$29.10
Intervallo di 1 settimana:
$26.25
$29.10
Portata 52W:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Confronta AGIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.93 | 1.67B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC) - The Globe and Mail
Is Agios Pharmaceuticals (AGIO) Offering A Compelling Entry Point After Recent Share Price Swings - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory - Finviz
Pharma News: Will Agios Pharmaceuticals Inc face regulatory challengesWeekly Gains Report & Daily Momentum Trading Reports - baoquankhu1.vn
What is Agios Pharmaceuticals Inc.’s market positionQuarterly Growth Report & Fast Moving Trade Plans - bollywoodhelpline.com
Q2 EPS Estimate for Agios Pharmaceuticals Boosted by Analyst - MarketBeat
A Look At Agios Pharmaceuticals (AGIO) Valuation After AQVESME FDA Approval And Commercial Launch - Sahm
Agios begins U.S. launch of thalassemia drug following FDA approval By Investing.com - Investing.com Nigeria
Is Agios’ AQVESME Thalassemia Launch and Sickle Cell Pathway Altering The Investment Case For Agios Pharmaceuticals (AGIO)? - Sahm
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sectors Review: Is Agios Pharmaceuticals Inc stock influenced by commodity pricesEarnings Performance Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline - MarketBeat
Agios Pharmaceuticals outlines 2026 strategic priorities - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Exploring a 29.77% Potential Upside in Biotechnology - DirectorsTalk Interviews
Weekly Recap: How Agios Pharmaceuticals Inc. stock valuations compare to rivalsWatch List & Accurate Buy Signal Notifications - Bộ Nội Vụ
Sickle Cell Disease Treatment Market is Thriving Worldwide | - openPR.com
Ideas Watch: Is Agios Pharmaceuticals Inc stock good for income investorsJuly 2025 Update & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Agios begins U.S. launch of thalassemia drug following FDA approval - Investing.com
Agios Pharmaceuticals Outlines 2026 Strategic Priorities and Milestones - TradingView — Track All Markets
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth - The Manila Times
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease ... - caledonianrecord.com
New anemia pill and sickle cell trials set up big year in rare disease care - Stock Titan
Published on: 2026-01-11 10:51:52 - ulpravda.ru
Peregrine Capital Management LLC Makes New $6.54 Million Investment in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
How Agios Pharmaceuticals Inc. stock performs in rate cut cycles2025 Big Picture & Technical Pattern Based Buy Signals - ulpravda.ru
Agios Pharmaceuticals plunges as Phase 3 sickle cell results deliver a mixed picture - MSN
(AGIO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
AGIO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money - ACCESS Newswire
What Wall Street predicts for Agios Pharmaceuticals Inc. stock priceJuly 2025 Patterns & AI Forecasted Entry and Exit Points - ulpravda.ru
What RSI levels show for Agios Pharmaceuticals Inc. (8AP) stockEarnings Recap Summary & Detailed Earnings Play Strategies - Улправда
Market Review: How Agios Pharmaceuticals Inc. stock responds to policy changesJuly 2025 Drop Watch & Technical Buy Zone Confirmation - Улправда
Why Agios Pharmaceuticals Inc. stock is seen as undervalued2025 Trade Ideas & High Return Trade Opportunity Guides - Улправда
How Agios Pharmaceuticals Inc. stock reacts to Fed rate cutsJuly 2025 Price Swings & Stepwise Trade Signal Guides - ulpravda.ru
How Agios Pharmaceuticals Inc. stock performs after earnings2025 Market WrapUp & Verified High Yield Trade Plans - Улправда
What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? - Yahoo Finance
Milanova, Agios Pharmaceuticals CCO, sells $77k in stock By Investing.com - Investing.com India
Milanova, Agios Pharmaceuticals CCO, sells $77k in stock - Investing.com
Bank of America Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO) - The Globe and Mail
Agios Pharmaceuticals CEO Goff sells $506,663 in stock By Investing.com - Investing.com Nigeria
Here's why shares in Agios Pharmaceuticals popped today - MSN
JP Morgan Raises Price Target for Agios Pharmaceuticals (AGIO) t - GuruFocus
Agios Pharmaceuticals, Inc. Being Investigated on Behalf of Agios Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Agios Pharmaceuticals, Inc. (AGIO): Investor Outlook Highlights A Potential 33% Upside - DirectorsTalk Interviews
JPMorgan Chase & Co. Boosts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $25.00 - MarketBeat
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - The Manila Times
How FDA Approval of First-in-Class Thalassemia Anemia Drug AQVESME Could Impact Agios Pharmaceuticals (AGIO) Investors - Sahm
Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,932 Shares of Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells $79,427.88 in Stock - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares - MarketBeat
Agios pharma chief legal officer Burns sells $79k in stock - Investing.com Canada
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):